JP2022522756A - 治療薬の送達のためのアデノ随伴ウイルスベクター - Google Patents

治療薬の送達のためのアデノ随伴ウイルスベクター Download PDF

Info

Publication number
JP2022522756A
JP2022522756A JP2021551562A JP2021551562A JP2022522756A JP 2022522756 A JP2022522756 A JP 2022522756A JP 2021551562 A JP2021551562 A JP 2021551562A JP 2021551562 A JP2021551562 A JP 2021551562A JP 2022522756 A JP2022522756 A JP 2022522756A
Authority
JP
Japan
Prior art keywords
cornea
gene
eye
sequence
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021551562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522756A5 (enExample
Inventor
アン・ジェイ・リゴッキ
カーメロ・ロマーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022522756A publication Critical patent/JP2022522756A/ja
Publication of JP2022522756A5 publication Critical patent/JP2022522756A5/ja
Priority to JP2024218892A priority Critical patent/JP2025061656A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021551562A 2019-02-28 2020-02-27 治療薬の送達のためのアデノ随伴ウイルスベクター Pending JP2022522756A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218892A JP2025061656A (ja) 2019-02-28 2024-12-13 治療薬の送達のためのアデノ随伴ウイルスベクター

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962812017P 2019-02-28 2019-02-28
US62/812,017 2019-02-28
US201962831838P 2019-04-10 2019-04-10
US62/831,838 2019-04-10
US201962878865P 2019-07-26 2019-07-26
US62/878,865 2019-07-26
PCT/US2020/020134 WO2020176747A1 (en) 2019-02-28 2020-02-27 Adeno-associated virus vectors for the delivery of therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218892A Division JP2025061656A (ja) 2019-02-28 2024-12-13 治療薬の送達のためのアデノ随伴ウイルスベクター

Publications (2)

Publication Number Publication Date
JP2022522756A true JP2022522756A (ja) 2022-04-20
JP2022522756A5 JP2022522756A5 (enExample) 2023-03-06

Family

ID=70155318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021551562A Pending JP2022522756A (ja) 2019-02-28 2020-02-27 治療薬の送達のためのアデノ随伴ウイルスベクター
JP2024218892A Pending JP2025061656A (ja) 2019-02-28 2024-12-13 治療薬の送達のためのアデノ随伴ウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218892A Pending JP2025061656A (ja) 2019-02-28 2024-12-13 治療薬の送達のためのアデノ随伴ウイルスベクター

Country Status (8)

Country Link
US (1) US20220047618A1 (enExample)
EP (1) EP3930694A1 (enExample)
JP (2) JP2022522756A (enExample)
CN (1) CN113557010A (enExample)
AU (2) AU2020229871B2 (enExample)
CA (1) CA3131919A1 (enExample)
IL (1) IL285639A (enExample)
WO (1) WO2020176747A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022216614B2 (en) 2021-02-05 2026-03-05 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
CN115505593B (zh) * 2021-06-23 2025-10-10 武汉纽福斯生物科技有限公司 寡核苷酸、病毒载体及其应用和RNAi药物制剂
US20250319202A1 (en) * 2021-11-09 2025-10-16 Prime Medicine, Inc. Genome editing compositions and methods for treatment of fuchs endothelial corneal dystrophy
WO2023111351A1 (en) * 2021-12-17 2023-06-22 Christian Kupatt Aav vectors for gene therapy in endothelial cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185054A1 (en) * 2016-04-22 2017-10-26 Intellia Therapeutics, Inc. Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
CN105899658B (zh) * 2013-12-12 2020-02-18 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
CN111206032B (zh) * 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
IL251178B (en) 2014-09-16 2022-07-01 Genzyme Corp Adeno-associated viral vector for the treatment of glaucoma myocilin (myoc)
PL3298134T3 (pl) * 2015-05-16 2023-09-18 Genzyme Corporation Edycja genów mutacji głęboko intronowych
AU2016335032B2 (en) * 2015-10-05 2022-04-14 Proqr Therapeutics Ii B.V. Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion
WO2017178590A1 (en) * 2016-04-14 2017-10-19 Université de Lausanne Treatment and/or prevention of dna-triplet repeat diseases or disorders
EP3342868B1 (en) * 2016-12-30 2019-12-25 Systasy Bioscience GmbH Constructs and screening methods
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
WO2018165541A1 (en) * 2017-03-10 2018-09-13 The Board Of Regents Of The University Of Texas System Treatment of fuchs' endothelial corneal dystrophy
CA3071769A1 (en) * 2017-07-31 2019-02-07 Reflection Biotechnologies Limited Cellular models of and therapies for ocular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185054A1 (en) * 2016-04-22 2017-10-26 Intellia Therapeutics, Inc. Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"AAV-mediated MMP-3 expression from corneal endothelium as a targeted gene therapy approach for glauc", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 57, JPN6023047173, 2016, pages 793, ISSN: 0005199618 *
"Capsid Mutated Adeno-Associated Virus Delivered to the Anterior Chamber Results in EEfficient Transd", PLOS ONE, vol. 10(6), e0128759, JPN6023047167, 2015, pages 1 - 16, ISSN: 0005199614 *
"Remarkably High and Selective Transgene Delivery Into Mouse Corneal Endothelium in vivo With Tyrosin", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 51, JPN6023047172, 2010, pages 2839, ISSN: 0005199615 *
"Transduction Profile of Anterior Chamber-injected Capsid Mutated Self-complementary Adeno-Associated", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 54, JPN6023047168, 2013, pages 2735, ISSN: 0005199616 *
GENE THERAPY, vol. 25, JPN6024031524, 2018, pages 402 - 414, ISSN: 0005390814 *
JOURNAL OF VIROLOGY, vol. 76, no. 15, JPN6024031523, 2002, pages 7651 - 7660, ISSN: 0005390813 *
MOLECULAR THERAPY, vol. Vol. 24, Supplement 1, JPN6023047169, 2016, pages 241 - 608, ISSN: 0005199617 *
STEM CELLS INTERNATIONAL, vol. Vol. 2019, Issue 1, JPN6024031525, 17 January 2019 (2019-01-17), pages 1 - 11, ISSN: 0005390815 *
日医大医会誌, vol. 13 (2), JPN6023047170, 2017, pages 88 - 96, ISSN: 0005199619 *

Also Published As

Publication number Publication date
WO2020176747A1 (en) 2020-09-03
CN113557010A (zh) 2021-10-26
EP3930694A1 (en) 2022-01-05
JP2025061656A (ja) 2025-04-11
IL285639A (en) 2021-09-30
US20220047618A1 (en) 2022-02-17
AU2020229871B2 (en) 2023-05-18
AU2020229871A1 (en) 2021-10-21
CA3131919A1 (en) 2020-09-03
AU2023216849A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US20260049334A1 (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
AU2019227726B2 (en) Novel adeno-associated virus (AAV) vectors, aav vectors having reduced capsid deamidation and uses therefor
RU2725286C2 (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP7467356B2 (ja) ハイブリッド調節要素
JP7023108B2 (ja) 組み換えａａｖバリアントおよびその使用
JP2025061656A (ja) 治療薬の送達のためのアデノ随伴ウイルスベクター
KR102527259B1 (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
CN105408352B (zh) 通过双重aav载体有效递送大基因
AU2018261003A1 (en) Compositions and methods of treating Huntington's Disease
KR20160033217A (ko) 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
JP2019533428A (ja) 標的遺伝子導入のための方法および組成物
US20240067984A1 (en) Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases
BR112020001940A2 (pt) modelos celulares de e terapias para doenças oculares
CA3018076A1 (en) Therapeutic for treatment of diseases including the central nervous system
CN120324641A (zh) 用于治疗达农病的基因治疗载体
JP2025518145A (ja) 修飾されたアデノ随伴ウイルスカプシドタンパク質及びその方法
US20220098614A1 (en) Compositions and Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)
US20230175015A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
EP4410988A1 (en) An aav2-vector variant for targeted transfer of genes
WO2009071679A1 (en) Novel aav vector and uses thereof
WO2025091025A1 (en) Gene therapy for ocular disorders relating to sirt1
CA3250230A1 (en) SPECIFIC PROMOTER OF THE HUMAN EPENDYMA AND ITS USES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241224